The FDA approved Eli Lilly’s Foundayo (orforglipron) on April 1, 2026, making it the first oral GLP-1 receptor agonist for weight management that can be taken at any time of day without food or water restrictions.

The approval covers adults with obesity (BMI ≥ 30) or overweight (BMI ≥ 27) with at least one weight-related condition. Foundayo is a once-daily pill — a small molecule, not an injectable peptide — that activates the GLP-1 receptor through the same pathway as semaglutide and tirzepatide.

The numbers: patients who stayed on the highest dose through 72 weeks lost an average of 12.4% of their body weight — roughly 27 pounds. In the intent-to-treat analysis (including those who discontinued), the average was 11.1%, or about 25 pounds.

The speed of this approval is worth noting. The FDA issued its decision 50 days after Lilly filed the application — 294 days ahead of the scheduled PDUFA date. That makes Foundayo the fastest new molecular entity approval since 2002. It was also the first approval under the National Priority Voucher Program.

Foundayo enters a market that now includes three oral GLP-1 options: Novo Nordisk’s Rybelsus (approved for type 2 diabetes) and the Wegovy pill (approved for weight management in December 2025, available January 2026). The key differentiator is convenience — both Novo Nordisk products require patients to take the pill on an empty stomach with limited water, then wait 30 minutes before eating. Foundayo has no such restrictions.

Prescriptions are being accepted immediately through LillyDirect, with shipping beginning April 6. Broad retail pharmacy availability is expected shortly after.